Drug Search Results
More Filters [+]

ACI-7104

Alternative Names: ACI-7104, ACI7104
Latest Update: 2024-09-21
Latest Update Note: Clinical Trial Update

Product Description

ACI-7104 is an optimized vaccine formulation designed to induce a-syn-specific antibodies recognizing aggregated a-syn species that are toxic to neurons. (Sourced from: https://www.acimmune.com/pipeline/clinical-trials/)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AC Immune
Company Location: 1015 LAUSANNE V8 00000
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ACI-7104

Countries in Clinic: Germany, Spain

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ACI-7104-PD-2103

P2

Unknown Status

Parkinson's Disease

2028-01-31

VacSYn

P2

Recruiting

Parkinson's Disease

2028-01-01

32%

Recent News Events